H-CYTE Inc. (QB) Stock Price - HCYT

Best deals to access real time data!
Small Cap Basic
Monthly Subscription
for only
$33.03
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
H-CYTE Inc. (QB) HCYT OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 0.17 0.00 0.00 0.00 0.17 16:00:05
Bid Price Ask Price Spread Spread % News
0.15 0.1848 0.0348 18.83% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.00 USD

H-CYTE Inc. (QB) Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 16.94M 99.67M - - 18.28M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
19.73k $ - 0.00% - -

more financials information »

H-CYTE Inc. (QB) News

Loading Messages....

Latest HCYT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HCYT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.134750.180.12940.160410174,5790.0352526.16%
1 Month0.110.180.090.131005167,7960.0654.55%
3 Months0.120.2990.060.13272278,7860.0541.67%
6 Months0.390.390.060.173625152,548-0.22-56.41%
1 Year0.500.6250.060.195105753,354-0.33-66.0%
3 Years0.500.6250.060.195105753,354-0.33-66.0%
5 Years0.500.6250.060.195105753,354-0.33-66.0%

H-CYTE Inc. (QB) Description

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX System, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. On October 18, 2018, MedoveX entered into an Asset Purchase Agreement with Regenerative Medicine Solutions, LLC, Lung Institute LLC ("LI"), RMS Lung Institute Management LLC ("RMS LI Management") and Cognitive Health Institute Tampa, LLC ("CHIT"),(collectively"RMS"). On January 8, 2019, the Asset Purchase Agreement was amended and the Company acquired certain assets and assumed certain liabilities of RMS. RMS was incorporated in Delaware on December 26, 2012. RMS is a healthcare medical biosciences company that develops and implements advance innovative treatment options in regenerative medicine to treat an array of debilitating medical conditions. In addition, the company is the operator and manager of the various Lung Health Institute clinics in Tampa, Nashville, Scottsdale, Pittsburgh, and Dallas To learn more about Medovex Corp., visit www.medovex.com.


Your Recent History
USOTC
HCYT
H-CYTE Inc..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.